Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: FatMatty who wrote (2329)	7/1/1998 3:43:00 PM
From: Mr. Forthright	Read Replies (1) \| Respond to of 5402

Sorry for ignoring your post. I incorrectly assumed you were just throwing out a number. Let me ask you a few questions then. 1) Is that the yearly market potential? 2) Could you please disclose the source for your estimate or how you came up with that number? I apologize again. I am looking forward to your answers.

To: FatMatty who wrote (2329)	7/1/1998 5:01:00 PM
From: Mr. Forthright	Read Replies (2) \| Respond to of 5402

Although we have yet to agree on some figures we are going in the right direction. The first three questions for the valuation model were: 1) What is the total market potential for synthetic red blood cell products? 2) What kind of market share/penetration is SGNC expected to achieve? 3)When is SGNC's product expected to get to market? Question 4 is: How many shares will be outstanding the year the product hits markets and in each of the following 5 years? I know you guys will think this is a trap but it is not. We are trying to determine a value per share today, so the starting point is some value per share in the future. That is why the number of shares is relevant. Let's get some answers now guys